SOLIGENIX INC (SNGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.38-0.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SNGX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -80.6% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 20.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SNGX — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-06-12
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 10, 2026, Soligenix, Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Listing Qualifications department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. T…
Why it matters: The company is at risk of delisting due to not meeting the $1.00 minimum bid price. Updates will signal compliance efforts.
Worry ifManagement shares a plan to meet Nasdaq listing rules again.
Less concerning ifThe company gets more notices or does not meet rules, raising delisting risk.
Why it matters: Management's look at options could lead to new partners or products. This may help growth.
Watch forManagement shares news about a new partnership. They also update progress on dusquetide.
Also watch forNo new plans are shared, showing no direction after stopping HyBryte.
Why it matters: Ending this program could hurt investor trust and future funding.
Worry ifA formal statement explains why the program ended and what comes next.
Less concerning ifA change in the termination decision or news showing the program can continue.
Why it matters: More shares can bring in money but may reduce the value of current shares.
Watch forA successful share offering raised more than $2.5 million.
Also watch forFailure to complete the share offering or a significant drop in share price.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$236 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $884 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,041 loss on $10,000 · 90.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Management's review of options may change their focus. This could affect how investors feel.
Watch forManagement shares a new plan or partnership for HyBryte or other assets.
Also watch forNo new options are taken, and the focus stays on current operations.
Why it matters: The company has little cash. Changes may affect how it operates and makes decisions.
Worry ifManagement says cash reserves are up due to new funding or share sales.
Less concerning ifCash reserves go down or stay the same, showing financial problems.
Why it matters: The company is looking at options like mergers. This may change its future.
Supportive ifThe company announces a merger or acquisition. This deal strengthens its position.
Worry ifNo strategic options are pursued, and the company continues on its current path without change.
Why it matters: Fixing the compliance issue is key. It helps keep the company's listing and investor trust.
Supportive ifThe company will meet the $1.00 minimum bid price by the next quarterly review.
Worry ifThe company does not regain compliance. This could lead to delisting.